Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: Results from an Asia-Pacific survey

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 1163-1170

  Olivares, Jose Manuel ^a   Thirunavukarasu, Manickam ^b   Kulkarni, Jayashri ^c   Zhang, Hong Yan ^d   Zhang, Mingyuan ^e   Zhang, Fan ^f  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

^c MONASH UNIVERSITY   (Australia)

^d PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^e SHANGHAI MENTAL HEALTH CENTER   (China)

^f Xian Janssen Pharmaceutical   (China)

Author keywords

Adherence; Antipsychotic; APAC; Schizophrenia; Survey

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AWARENESS; CONTROLLED STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PREFERENCE; PERCEPTION; PHYSICIAN ATTITUDE; PSYCHIATRIST; QUESTIONNAIRE; SCHIZOPHRENIA;

EID: 84881494765     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S49080     Document Type: Article

References (25)

1. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry. 2006;67(Suppl 5):9-14.
2. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry. 2003;64(11): 1308-1315.
3. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatr Res. 2008;161(2):235-247.
4. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
5. Karagianis J, Novick D, Pecenak J, et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract. 2009;63(11):1578-1588.
6. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
7. Stroup TS, Lieberman JA, McEvoy JP, et al; CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611-622.
8. McEvoy JP, Lieberman JA, Stroup TS, et al; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-610.
9. Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry. 2009;11(4):147-154.
10. McEvoy JP, Howe AC, Hogarty GE. Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenic patients. J Nerv Ment Dis. 1984;172(7): 412-416.
11. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2-3):109-113.
12. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247.
13. Velligan DI, Weiden PJ, Sajatovic M, et al, for Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness Collaborators. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1-46.
14. Kane JM. Treatment adherence and long-term outcomes. CNS Spectrums. 2007;12(10 Suppl 17):21-26.
15. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(Suppl 9):5-9.
16. Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004;184:509-516.
17. Giner J, Cañas F, Olivares JM, et al. Treatment adherence in schizophrenia. A comparison between patient's, relative's and psychiatrist's opinions. [Article in Spanish]. Actas Esp Psiquiatr. 2006;34(6):386-392.
18. Olivares JM, Alptekin K, Azorin JM, et al. Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East and Africa. Patient Prefer Adherence. 2013;7:121-132.
19. World Health Organization. Mental Health Atlas-2011 country profiles. Available at: http://www.who.int/mental_health/evidence/atlas/profiles/en/index.html. Accessed June 19, 2013.
20. World Health Organization. The global burden of disease: 2004 update. Geneva, Switzerland: World Health Organization; 2004:32.
21. Naber D, Alptekin K, Azorin JM, et al. The EMEA ADHES survey in schizophrenia: psychiatrists' perceptions of the extent of assessment and management of partial and non-adherence to medication [P03-277]. Eur Psychiatry. 2011;26(S1):1446.
22. Razali SM,Prevention of relapse and interventions for enhancing medication adherence in schizophrenia: An East Asian perspective. Asia-Pacific Psychiatry. 2010;2(2):68-76.
23. Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009;24(5):287-296.
24. Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review Schizophr Res Treatment. 2012;2012:407171. Epub February 15, 2012.
25. Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005;133(2-3):129-133.